China Approves First Commercially Available Brain-Computer Interface, Signaling Ambitions in Neurotechnology
In a landmark move that positions China at the forefront of neurotechnology, the National Medical Products Administration (NMPA) has granted approval for the commercial sale of Neo, an implantable brain-computer interface (BCI) developed by Neuracle Medical Technology. This marks the first time globally that an invasive BCI has received regulatory clearance for leverage in patients, opening a new chapter in the treatment of paralysis and sparking a wave of investment in the burgeoning Chinese BCI industry. The device, designed to restore hand motor function in individuals with spinal cord injuries, translates neural signals into movements of a robotic hand, offering a potential lifeline to those with limited mobility.
The approval, announced on March 13, 2026, underscores China’s accelerating push to become a global leader in brain-computer interface technology. Shares of BCI companies listed on mainland Chinese exchanges surged following the announcement, with Shenzhen-listed Inkon Life Technology experiencing a gain of over 10 percent, demonstrating investor confidence in the sector. This regulatory milestone isn’t occurring in isolation. it’s part of a broader, strategic initiative by the Chinese government to cultivate a competitive BCI industry within the next five years, fueled by both regulatory support and substantial capital investment.
Neuracle, a private firm founded in 2011, secured the approval after 18 months of testing that demonstrated the safety and efficacy of the Neo implant. The company’s founder, Xu Honglai, holds a PhD in biomedical engineering from Tsinghua University, a leading Chinese institution. The device itself is described as being approximately the size of a coin, with eight electrodes that are placed on the surface of the brain – specifically, the area responsible for processing body movement. When a patient imagines moving their hand, the implant transmits a signal to a computer, which then translates that intention into actions performed by a prosthetic device, such as a mechanical glove capable of grasping objects or performing everyday tasks.
Restoring Function and a New Era for BCI Technology
The Neo implant is intended for individuals aged 19 to 60 who have experienced paralysis due to injuries to the neck or spinal cord, resulting in the loss of limb function. Clinical trials involving 32 participants have reportedly shown no adverse side effects, according to reports. While several companies worldwide are actively developing BCI technologies, including the high-profile Neuralink founded by Elon Musk, Neuracle is the first to achieve commercial approval for an invasive device. Neuralink, and other advanced projects, have faced hurdles related to safety concerns and regulatory scrutiny, delaying their path to market. The NMPA’s decision represents a significant departure, signaling a willingness to embrace and regulate this potentially transformative technology.
The implications of this approval extend beyond the immediate benefits to patients with paralysis. The successful development and commercialization of Neo demonstrate the feasibility of invasive BCI technology and pave the way for further innovation in the field. Researchers are exploring a wide range of potential applications for BCIs, including restoring communication for individuals with locked-in syndrome, controlling prosthetic limbs with greater precision, and even treating neurological disorders such as Parkinson’s disease and epilepsy. The ability to directly interface with the brain opens up possibilities previously confined to the realm of science fiction.
China’s Strategic Plan for BCI Dominance
The timing of this approval is closely linked to a comprehensive policy document released by China outlining its strategy to establish a globally competitive BCI industry. This plan, encompassing 17 specific steps, aims to foster research, development, and application of BCI technologies across various sectors. According to Phoenix Peng, cofounder of NeuroXess and Gestala, both BCI companies, the government’s support is crucial. “The Chinese government has always supported disruptive technologies. I think from the government’s point of view, this policy means that BCI technology has already moved from the concept level to the product level,” Peng stated earlier this year.
The policy document prioritizes not only invasive implants like Neo but as well the mass production of non-invasive BCI devices, including those mounted on the forehead, head, or ears – similar in form factor to hearing aids, visors, or glasses. The plan proposes testing these technologies in high-risk industries, such as hazardous materials handling, nuclear energy, mining, and electricity generation, potentially enhancing worker safety and efficiency. This broad approach suggests a long-term vision for integrating BCI technology into various aspects of Chinese society and industry.
The Chinese government’s commitment to BCI technology is further evidenced by recent funding rounds for BCI startups. Shanghai-based StairMed Technology recently secured 500 million yuan (approximately US$72.6 million) in a funding round led by Alibaba Group Holding, bringing its total funding in the past year to 1.1 billion yuan. This influx of capital will undoubtedly accelerate the development and commercialization of new BCI technologies in China. Neuracle itself was already in the process of listing on the Star Market of the Shanghai Stock Exchange, signing an initial public offering tutoring agreement with Citic Securities prior to the NMPA approval.
Global Implications and Future Outlook
China’s rapid advancement in BCI technology has significant implications for the global landscape. The country’s regulatory framework, coupled with substantial investment and a clear strategic plan, positions it as a major player in this emerging field. While companies like Neuralink continue to push the boundaries of BCI technology in the United States, they face a more complex regulatory environment and ongoing scrutiny regarding safety and ethical concerns. The approval of Neo in China demonstrates a different approach, one that prioritizes innovation while establishing a framework for responsible development and deployment.
The initial focus of brain implants remains on restoring autonomy to individuals with disabilities. However, the potential applications of BCI technology extend far beyond this. Researchers are exploring devices that allow users to communicate through thought, operate computers without physical movement, and even restore vision. As technology advances and regulatory hurdles are overcome, we can expect to notice a wider range of BCI applications emerge, transforming healthcare, industry, and potentially even human capabilities. The commercial launch of Neo marks not just a milestone for Neuracle, but a turning point for the entire brain-computer interface industry.
Looking ahead, the next key development to watch will be the expansion of clinical trials and the broader availability of the Neo implant to patients in China. Further updates from Neuracle regarding manufacturing capacity, distribution plans, and long-term clinical outcomes will be crucial in assessing the impact of this groundbreaking technology. The NMPA will also likely continue to refine its regulatory framework for BCI devices, balancing innovation with patient safety and ethical considerations. The world will be watching closely as China continues to lead the charge in this rapidly evolving field.
What are your thoughts on the ethical implications of brain-computer interfaces? Share your comments below and join the conversation.
Related reading